ロード中...
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
The epidermal growth factor receptor (EGFR), which participates in signalling pathways that are deregulated in cancer cells, is frequently mutated in colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We evaluated the efficacy of cetuximab in weekly combin...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2006
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361373/ https://ncbi.nlm.nih.gov/pubmed/16508634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603018 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|